Auto Draft

Absci Corp. (NASDAQ:ABSI) is one of the 10 Stocks Investors Are Dumping Right Now.

Absci Corp. dropped for a third straight day on Monday, slashing 11.54 percent to end at $7.48 apiece after receiving a price target cut for its stock.

In a market note, Guggenheim Securities reduced its price target to $14 from $15 previously, while maintaining a buy recommendation, after technically adjusting its model to a fully diluted share count in its discounted cash flow analysis. It said that the stock may be particularly volatile into and around the December data.

Photo by Tima Miroshnichenko on Pexels

The target cut followed Absci Corp.’s earnings performance in the third quarter of the year, where it registered a 16 percent higher net loss of $33.3 million versus $28.7 million in the same period last year.

Absci Corp. remains a pre-revenue company, having no commercial sales yet, although it earns from partner programs.

Partner program revenues during the period stood at $304,000 versus $378,000 year-on-year.

Last week, the company named Gerry Muhle as its new chief commercial officer to lead commercialization of prescription medicines and build consumer brands to advance ABS-201 and the company’s broader pipeline.

Muhle brings more than 25 years of commercial leadership experience, having led multiple successful product launches across prescription medicines, aesthetics, and consumer skincare, and held full P&L responsibility for major businesses at his previous companies.

Prior to Absci Corp., Muhle served as Senior Vice President and Head of Global Product Strategy for Galderma, where he led global commercial and product strategy across the company’s entire portfolio, spanning all three businesses: therapeutic dermatology, injectable aesthetics, and dermatological skincare.

READ NEXT: Forget Nvidia: 10 Stocks Wall Street is Betting on Right Now and Buy Alert: 10 Stocks Analysts Upgraded on Friday

Follow Insider Monkey on Google News.